On May 5, a panel of experienced industry experts will discuss recent developments during Innovations in Drug Delivery, a free one-hour industry webinar.
In this first part of a series on the state of clinical research, an expert shares insightful ideas on how to improve patient experience and study results.
A leader from the CRO talks about increased use of electronic patient-reported outcomes in research, challenges of adoption, and how ePRO benefits trials.
The two companies plan to collaboratively explore ways to combine 3D printing and nanotechnology, in order to create nanoparticle-enabled dosage forms.
The chairman, president and CEO of Thermo Fisher says the acquisition stands to benefit clinical trial and drug development clients in a long list of ways.
Published by Tabula Rasa Healthcare, the report looks at the MedWise Risk Score, technology designed to determine ADE risk rising from medication regimens.
The 6th annual Clinical Research as a Care Option conference, taking place April 26-27, brings together experts seeking solutions to elevate the industry.
An advanced cancer detection platform from C2i Genomics (reportedly capable of spotting miniscule traces of the disease) recently landed $100m in funding.
Leaders from AmerisourceBergen's World Courier and Lash Group tell how bringing trial supplies and services to patients can boost recruitment and retention.
A leader from the laboratory solutions provider talks about how the virus has created challenges for researchers, and how those obstacles might be cleared.
ImmunoScape plans to use the investor funds to grow its Asia presence, expand into the US, and to further develop its Deep Immunomics platform technology.
The two technology companies plan to work together to provide a unified platform that serves to streamline workflow, RWE generation and data harmonization.
A leader from digital health solutions firm CitiusTech suggests use of fast healthcare interoperability resources is useful in the face of evolving tech.
One Health’s FidoCure is using genomics and AI technology to develop precision oncological treatments, and the work is benefiting human cancer research.
The science service and technologies firm plans to bring the CRO under its Laboratory Products and Services Segment umbrella after the deal is completed.
The Institute for Clinical and Economic Review will use Aetion observational real-world evidence to evaluate potential drugs from Takeda and CSL Behring.
The two companies have partnered to develop a systemic erythematosus assessment review to streamline clinical trials centered on the autoimmune disease.
The collaboration centers on development of precision cancer treatments, through discovery and validation of next-generation DNA damage response targets.
Leaders from the supply chain solutions company share their thoughts on challenges associated with virtual and hybrid trials, and the COVID-19 pandemic.
New research findings suggest that an immunotherapy assay enables determination of PD-L1 status in a high percentage of cancer patients and could guide personalized treatment selection.
The AWARE for All virtual event series aims to educate and engage the public as important partners in clinical trials and development of new treatments.
A leader from the global CRO discusses how putting the patient first in clinical research is essential to discovering new therapies for orphan diseases.
Especially with the COVID-19 pandemic impacting studies, the company says, putting patients at the center of studies and trial tech must be top priority.
A father of two boys with Duchenne muscular dystrophy is running the Austin Marathon to raise funds toward pursuit of a cure for the rare, fatal disease.
The free Patient-Centric Trial Development Toolkit is aimed toward helping sites and sponsors identify and minimize risks in rare-disease clinical studies.
The clinical research tech specialists, which had held 60% of Q2 Diagnostics, will now wholly own the comprehensive clinical laboratory services company.
The advanced biotech analysis company is harnessing the power of a formidable supercomputer to discover potential treatments for the virus and mutations.
Artificial intelligence software company Thirona has released PRAGMA-AI, technology that automates and accelerates CT scans in cystic fibrosis analysis.
A couple of new developments to report in relation to Merck, known as MSD outside the US and Canada: the first being the rejection by the US FDA of the company’s application to use its anti-PD-1 therapy, Keytruda, in certain breast cancer patients.
According to a Veeva Systems survey, contract research organizations are working to ensure clinical trials keep going during the COVID-19 era and beyond.
An expert speaking at the April 6 Clinical Development Innovations event will discuss an app that matches patients with clinical research opportunities.
A representative of the rare-disease specialist firm outlines the unique obstacles of orphan CNS disease research, and how professionals can overcome them.
A survey by the Pistoia Alliance indicates most professionals believe the tech can accelerate R&D, but companies are stymied by a skills gap and data bias.
The two companies will work together to evaluate the combination of SLC-391 and Keytruda in treating patients with advanced non-small cell lung cancer.
Two experts from CRO Phastar talk about how trial professionals face new, ever-changing challenges regarding collecting and disseminating patient data.
The company’s Patient Advisory Council brings together a range of people and perspectives to help ensure increased diversity, inclusivity and engagement.
The company reports that its patient-centric virtual study technology currently is in use in more than 60 ongoing trials in over 40 different countries.
Health Union offers patients dealing with a range of conditions ways to connect with valuable information, research opportunities and each other online.
A new report from the organization forecasts a wave of pharma innovation over the next four years could lead to 75 FDA drug approvals annually by 2025.
